Category: Case Study
Oversight Monitoring Successes A biopharmaceutical company engaged Catalyst Flex to provide appropriate and impartial oversight monitoring for several studies. Such services can help to prevent a sponsor from receiving findings during U.S. Food and Drug Administration (FDA) audits and in particular any Form FDA 483. Read Now 
Comprehensive and Flexible Partnership to Support Rescue Study A biotech company new to clinical research with an asset early in its development lifecycle became a long-term partner with Catalyst Flex. For years, Catalyst has worked alongside to help achieve the client’s goals for a single asset for the first bladder cancer therapy on the horizon in the past 20 years. Read Now 
Focused Monitoring Support for Rare Disease Study A small biotech needed functional support for a Phase III rare disease study. Although a contract
existed between the biotech and a clinical research organization (CRO), the study timelines and budget
had slipped. The biotech hired Catalyst Flex to reverse that trend and ultimately saved ~$1 million. Read Now 
Catalyst Flex on Rapid CRA Deployment Catalyst Flex provides expert clinical research professionals Catalyst Flex engages highly skilled and experienced industry Read Now 
Partnering to Overcome Compliance Challenges Catalyst Flex Partners with TrialKit An innovative medical device company contracted with Catalyst Flex for Read Now 
Executive Safety Support Long-term global pharmacovigilance assistance Catalyst Flex provided a range of pharmacovigilance services for an active Read Now 
Safe and Sound Supporting pharmacovigilance during global expansions Catalyst Flex contracted for studies across several indications and countries. Read Now 
Rapid First Person In Milestone Less than 2 months for an oncology drug and device development company A drug and Read Now 
Catalyst Oncology FIH Rescue Study A clinical-stage biotech company with a critical startup milestone Catalyst Oncology transitioned full-service work from Read Now 
Global Full-service Phase III Ovarian Cancer Study Catalyst Oncology succeeds in delivering for late clinical-stage oncology biotech. While the biotech had experience Read Now